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reduction in diabetes related complications and the lower frequency of SMBG 
tests. Remaining extra annual costs for SAP were 1,258 € per patient. When indirect 
costs were considered, the ICER was reduced to 23,300 € per QALY. ConClusions: 
Using a well-accepted simulation model in an uncontrolled T1DM, projection of 
the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in France. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range 
of assumptions.
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to PrEvEnt tyPE 2 DiABEtEs AMong ADults With iMPAirED gluCosE 
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objeCtives: To investigate the costs and cost-effectiveness of a short message 
service (SMS) intervention to prevent the onset of type 2 diabetes mellitus (T2DM) 
in subjects with impaired glucose tolerance (IGT). Methods: A Markov model was 
developed to simulate the cost and effectiveness outcomes of the SMS interven-
tion and usual clinical practice from the health service provider’s perspective. The 
annual transition probabilities between health states were taken from several 
data sources, including Diabetes Prevention Program and Diabetes Prevention 
Program Outcome Study. The direct program costs and the two-year SMS interven-
tion costs were evaluated in subjects with IGT. All costs were expressed in year 
2011 U.S. dollars. The incremental cost-effectiveness ratio were calculated as cost 
per T2DM onset prevented, cost per life year gained and cost per quality adjusted 
life year (QALY) gained. Both base-case scenario and sensitivity analysis were 
conducted. Results: Within the two-year trial period, the net intervention cost 
of the SMS group was $42.03 per subject. The SMS intervention managed to reduce 
5.05% onset of diabetes, resulting in saving $118.39 per subject over two years. 
In the lifetime model, the SMS intervention dominated the control by gaining 
an additional 0.071 QALY and saving $1020.35 per person. The SMS interven-
tion remained dominance in all sensitivity analyses. ConClusions: This study 
revealed that the SMS intervention for subjects with IGT had the superiority of 
lower monetary cost and a considerable improvement in preventing or delaying 
the T2DM onset.
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Cost-MiniMisAtion AnAlysis of DAPAgliflozin CoMPArED to 
lixisEnAtiDE As An ADD-on to insulin in thE trEAtMEnt of tyPE 2 
DiABEtEs MEllitus froM A uk hEAlth CArE PErsPECtivE
Vioix H.1, Eddowes L.A.2, Griffiths M.2, Gabriel Z.1
1AstraZeneca UK Ltd., Luton, UK, 2Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: To evaluate the cost of using the first-in-class sodium-glucose co-
transporter-2 (SGLT-2) inhibitor dapagliflozin compared to the glucagon-like pep-
tide-1 (GLP-1) analogue lixisenatide, when added to insulin for the treatment of 
patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled on 
insulin alone. Methods: Bucher indirect comparisons and a network meta-analy-
sis were performed in the add-on to insulin population with regards to the key T2DM 
outcomes of HbA1c, weight and hypoglycaemia. Dapagliflozin had similar treat-
ment effects to lixisenatide, with no statistically significant differences between 
dapagliflozin and lixisenatide in these outcomes. Therefore, a cost-minimisation 
analysis over a 1-year time horizon was developed from a UK health care perspec-
tive. Drug and administration costs, including a nurse consultation, were considered 
in the model. Drug costs were those of the British National Formulary (September 
2013), device costs were taken from the Information Services Division Drug Tariff 
2013 and the cost of a nurse consultation was estimated using the Unit Costs of 
Health and Social Care report compiled by the Personal Social Services Research 
Unit. The application of an annual discount rate of 3.5% and use of a longer time 
horizon (up to 5 years) were explored in scenario analyses. Results: Dapagliflozin 
was associated with a yearly cost of £476.96 per patient. The cost per patient for 
lixisenatide was £765.76 in the first year and £752.07 in subsequent years. Therefore, 
dapagliflozin was cost-saving compared to lixisenatide, driven by the difference 
in drug and administration costs. Applying the annual discount rate and using a 
longer time horizon, dapagliflozin was associated with savings of £1,255.30 over 5 
years compared to lixisenatide. ConClusions: Dapagliflozin in combination with 
insulin was shown to be a cost-saving treatment option compared to lixisenatide 
from a UK health care perspective for patients with T2DM who are inadequately 
controlled on insulin alone.
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EConoMiC EvAluAtion of lAnrEotiDE AutogEl in thE MAnAgEMEnt of 
ACroMEgAly in grEECE
Kousoulakou H.1, Panayiotou-Pazaitou K.2, Pantazi E.3, Tsentidis C.4, Tzanela M.5, Vryonidou 
A.6, Markussis V.7, Eleftheriou C.7, Geitona M.1
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objeCtives: Acromegaly is a chronic and debilitating disease, which can lead 
to significant increases in health care costs. The objective of the present study 
was to undertake an economic evaluation of Lanreotide Autogel compared with 
Octreotide LAR in the management of acromegaly in the Greek health care set-
ting. Methods: A cost minimization model was developed for the analysis which 
only considers the costs of treatment, as the two drugs have equal efficacy. The 
time horizon was 30 years; future costs were discounted at 3.5%. In addition, 
a budget impact analysis was conducted, with a time horizon of 5 years. The 
perspective for both analyses was that of Social Insurance. Data on resource use 
(administration setting, drug wastage and time required for the administration of 
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objeCtives: To synthesize and analyze the available information on the thera-
peutic value of dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 
diabetes mellitus (T2DM) from the point of view of their efficiency or cost-effective-
ness. Methods: A systematic review of national (MEDES, IBECS) and international 
(MedLine/PubMed, Cochrane Library, ISI WOK, SCOPUS) databases was performed. 
Eligible studies were economic evaluations (cost-effectiveness, cost-utility and cost-
benefit analysis) comparing costs and clinical benefits of two alternatives for the 
T2DM treatment including DPP-4 inhibitors, published in English or Spanish until 
June 2013. Studies providing data concerning costs and/or disease burden only were 
excluded. Results: Of 1,634 publications initially selected, 284 were excluded by 
duplicate review, 1,330 by title/abstract review and 8 by criteria accomplishment. A 
total of 12 publications [1 conducted in 6 countries including Spain, 4 in Europe, 4 
in USA and 3 in others] were selected. All studies were cost-effectiveness or cost-
utility analysis [discrete-event simulation (n= 8), Markov (n= 3) and others (n= 1)] 
Time horizon ranged from one year (n= 1) to lifetime (n= 7), considering 20 years 
(n= 1), 35 years (n= 2), and 40 years (n= 1). National Health System perspective was 
adopted in all publications (n= 12). One study did not include a sensitivity analysis. 
Results showed that T2DM therapy with DPP-4 inhibitors and metformin resulted 
cost-effective compared with sulfonylureas plus metformin in all countries which 
were evaluated (Sweden, UK, Germany, Portugal, Austria, Finland, Spain, USA and 
Argentina). Although DPP-4 inhibitors cost was higher compared with sulfonylureas, 
DPP-4 inhibitors plus metformin were associated to higher clinical benefits versus 
sulfonylureas plus metformin in terms of decreasing hypoglycemia incidence and 
T2DM complications. ConClusions: DPP-4 inhibitors added to metformin are a 
cost-effective alternative compared with sulfonylureas plus metformin in T2DM 
patients, mainly due to a lower hypoglycemia incidence and T2DM complications.
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DiABEtEs, A uk PErsPECtivE
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) of 
type 1 diabetes (T1DM) in the UK. Methods: The Core Diabetes Model was used 
to project the incidence of diabetes-related complications over a lifetime horizon, 
based on A) a published meta-analysis comparing SAP versus CSII, and B) a real 
life observational study. The meta-analysis showed that for the analysed cohort of 
T1DM with average baseline HbA1c of 10%, every day use of SAP led to a reduction 
of -1.49% versus -0.62% HbA1c, for CGM and CSII respectively. The mean baseline 
age of the simulated cohort was 27 years, with a mean duration of diabetes of 13 
years. SAP effects also included a decrease in the annual rate of major hypoglycae-
mic events from 2.2 events per 100 patients’ month for CSII to 0. The quality of life 
was adjusted for a reduced fear of hypoglycaemic event in the SAP arm. Sensitivity 
analyses were carried out on several key parameters. Results: The incremental 
cost-effectiveness ratio (ICER) was 16,986 GBP (£) per Quality Adjusted Life Year 
gained (QALY). The improvement in discounted QALY was 3.1 years in favour of SAP. 
Additional SAP related costs were partially offset by the savings due to the reduction 
in diabetes related complications and the lower frequency of SMBG tests. Remaining 
extra costs due to SAP were on average 1,143£ per year. When a societal perspective 
was considered, ICER was reduced to 8,462 £ per QALY. ConClusions: Projection 
of the improvement in HbA1c of SAP versus CSII translated into cost-effective ratio, 
generally considered as very good value for money in the UK. Extensive sensitivity 
analysis on key drivers confirmed the robustness of results under a wide range of 
assumptions.
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objeCtives: The main objective of this study was to estimate the health-economic 
impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) 
in uncontrolled type 1 diabetes (T1DM) in France. Methods: The Core Diabetes 
Model was used to project the incidence of diabetes-related complications over 
a lifetime horizon, based on a recently performed meta-analysis comparing SAP 
versus CSII. The meta-analysis showed that for the analysed cohort of T1DM using 
exclusively Medtronic devices with average baseline HbA1c of 9%, 70% use of SAP 
led to a reduction of -0.88% versus -0.47% HbA1c, for SAP and CSII respectively. 
The mean baseline age of the simulated cohort was, according to a French typi-
cal TD1M population, 36 years, with a mean duration of diabetes of 17 years. The 
quality of life was adjusted for a reduced fear of hypoglycaemic event in the SAP 
arm. Sensitivity analyses were carried out on several key parameters. Results: 
The incremental cost-effectiveness ratio (ICER) was 27,796 € per Quality Adjusted 
Life Year gained (QALY). The improvement in discounted QALY was 1.27 years in 
favour of SAP. Undiscounted life expectancy was increased by 1 year for SAP versus 
CSII. Additional SAP related costs were partially offset by the savings due to the 
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equations/algorithms from the UKPDS Outcomes Model (68) to predict the long 
term risks of type 2 diabetes-related complications. The impact of treatments 
on risk factors and side effects was based on clinical trials, observational stud-
ies, systematic reviews and meta-analyses of relevant RCTs, as well as the most 
recent findings on the potential benefit of DPP4 on other-cause mortality and 
cardiovascular diseases and the possible detrimental effect of sulfonylurea on 
myocardial infarction (MI). European patient profiles and Belgium-specific data 
on drug prices, diabetes-related complication treatment costs, treatment patterns 
and guidelines were used. Results: A sitagliptin-based treatment strategy was 
projected to cost € 1,102 more than a sulfonylurea-based treatment strategy per 
patient lifetime, with the majority of excess costs from prescription drugs. Life 
expectancy was 0.077 years greater per patient on a sitagliptin-based strategy 
compared to a sulfonylurea-based strategy. The discounted gain in QALY was 0.082 
years with the sitagliptin-based strategy, driven by better hypoglycemia, weight, 
and MI risk profile. The estimated ICER was € 13,460/QALY. Sensitivity analyses 
demonstrated that the ICER was somewhat sensitive to the price of sulfonylureas 
and the weight utility decrement, and most sensitive to assumptions on relative 
risk parameters. When no relative risk reduction on MI or other-cause mortality 
was assumed, the ICER was € 17,543/QALY and € 17,053/QALY, respectively. When 
no relative risk reduction on either MI or other-cause mortality was assumed, the 
ICER increased to € 23,691/QALY. ConClusions: Using a threshold of € 15,000 per 
QALY gained, compared to a sulfonylurea-based treatment strategy, a sitagliptin-
based treatment strategy was cost-effective in metformin-failed patients with 
type 2 diabetes in Belgium.
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objeCtives: Type 2 diabetes (T2D) patients on basal insulin with uncontrolled 
HbA1c levels often receive an add-on with bolus insulin to lower HbA1c levels. 
The aim of this analysis is to estimate long-term cost-effectiveness of treating 
T2D patients with – a recently introduced – twice daily (BID) exenatide add-on to 
basal insulin strategy from a Turkish health care perspective. Methods: Clinical 
inputs for both treatment strategies were taken from the GWDM clinical trial. The 
strategies were assessed using a micro-simulation disease model (CARDIFF). The 
model predicted micro-and macro-vascular complications based on the UKPDS 
equations. The incidence of adverse events, diabetes related complications and 
changes in body weight yielded estimates of health care costs and health utilities. 
The direct (T2D and complication) costs in the model reflect the Social Security 
Institution costs. Discounting both costs and effects at 3% over the 40 year follow-
up of the model, resulted in life time estimates of costs and quality-adjusted life 
years (QALYs) on both treatment strategies. Deterministic and probabilistic sensi-
tivity analyses, as well as elaborate scenario analyses were performed. Results: 
Results showed that exenatide treatment significantly improves QALYs by 0.60 (95% 
CI: 0.24 to 0.97). Health effects were reached at an additional cost of 217 $ (95% CI: 
-356$ to 976$), resulting in an incremental cost-effectiveness ratio of 362 $ per QALY 
gained. Scenario analyses showed that these results were robust to changes in 
input parameters. At a willingness-to-pay threshold of 30,000 $/QALY the exenatide 
strategy had a near 100% probability of being cost-effective compared to bolus insu-
lin. ConClusions: A twice daily exenatide add-on to basal insulin treatment for 
T2DM patients with uncontrolled HbA1c levels is considered a highly cost-effective 
strategy from the Turkish public health care perspective.
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CoMPArAtivE Cost-EffECtivEnEss AnAlysis of ADDing tWiCE-DAily 
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1AstraZeneca, Madrid, Spain, 2Pharmerit International, Rotterdam, The Netherlands
objeCtives: When HbA1c is elevated above target in Type 2 diabetes (T2D) patients 
treated with basal insulin, the widespread strategy consists of adding mealtime 
insulin. An alternative option is adding twice-daily exenatide (BID), a glucagon-like 
peptide-1 receptor agonist. The objective was to estimate the cost-effectiveness in 
Spain of exenatide BID compared to mealtime bolus insulin lispro, both added to 
insulin glargine and metformin. Methods: The published and validated CARDIFF 
long-term diabetes model was used to estimate the direct medical costs and quality-
adjusted life years (QALYs) associated with each strategy. Patient characteristics at 
baseline, efficacy and safety inputs were all derived from a head-to-head, double-
blind, randomized controlled trial (NCT00960661), comparing both strategies for 
30 weeks. Based on the United Kingdom Prospective Diabetes Study-68 equations, 
the model predicted long-term disease progression and occurrence of micro- 
and macro-vascular complications, including mortality. Costs and utilities were 
assigned to complications, hypoglycaemias, adverse events and body mass index 
changes. The analyses were performed from the perspective of the Spanish health 
care payer, over a lifetime horizon, at a discount rate of 3% (costs and health out-
comes). Univariate and probabilistic sensitivity analyses were conducted. Results: 
Treatment with exenatide BID was projected to produce an incremental benefit of 
0.61 QALYs (95 % CI: 0.26 to 0.99) compared to treatment with insulin lispro, at an 
additional cost of € 146 (95% CI: -€ 1,114 to € 1,679) resulting in an incremental cost-
effectiveness ratio of € 239 per QALY gained. The exenatide BID strategy reached a 
probability near 100% of being cost-effective at a willingness-to-pay threshold of 
€ 2,500 per QALY gained. Sensitivity analyses showed that results were robust to vari-
ation in range of model parameters. ConClusions: Exenatide BID was predicted 
to be a cost-effective treatment alternative to mealtime bolus insulin in Spain for 
T2D patients not at target with insulin glargine.
each drug), as well as lab and imaging tests, were collected with the Delphi tech-
nique via an expert panel with 11 experienced endocrinologists, from University 
and Public Hospital specialized units. Local unit cost data were collected from 
officially published sources (Ministry of Health and Social Insurance Funds). One 
way sensitivity analyses were performed to test the results. Results: Lanreotide 
Autogel reduced total costs of acromegaly treatment by € 29,896 per patient over 
the 30-year time horizon. 93% of the savings were attributed to the reduction in 
drug acquisition and administration costs. Discount rate was the most influential 
parameter in the sensitivity analysis. The total cost of managing acromegaly in 
Greece, including lab and imaging tests, over a 5-year time horizon was estimated 
to range between € 22.9 and € 22.2 million, with a 30% and 60% market share for 
Lanreotide Autogel, respectively. Therefore, doubling Lanreotide Autogel’s share 
would lead to total savings of € 781,604. ConClusions: Lanreotide Autogel in 
comparison with Octreotide LAR may result in a reduction of the total cost in the 
management of acromegaly in Greece.
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thE oPPortunity of trEAting tyPE ii DiABEtEs With DPP4i: An EConoMiC 
EvAluAtion vErsus ConvEntionAl trEAtMEnt in thE itAliAn sEtting
Lorenzoni V., Pierotti F., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: To compare dipeptdyl-peptidase 4 inhibitors (DPP4i) and sulfonylurea 
(SU) for the treatment of type II diabetes mellitus in terms of economic impact and 
considering both the Italian National Health System (NHS) and the societal perspec-
tive. Methods: The economic evaluation was performed as a model-based cost-
minimization analysis for the comparison DPP4i and SU as second line therapy, in 
add-on to metformin, over 1-year period. Clinical events to be included in the model 
were selected from literature review and the opinion of a panel of clinical experts. 
Resources used were quantified and valued adopting costs and tariffs related to 
drugs used, glycaemic auto-monitoring, established control visits, incidence of 
hypoglicaemic events, macrovascular complications and the switch to insulin 
therapy. One-way sensitivity analyses for model inputs were conducted. Results: 
Due to the higher cost for drug acquisition in the base case analysis total direct costs 
for the Italian NHS were about 728 Euro per patient/year in the case of DPP4i and 
on average 702 Euro for SU. The overall yearly cost for the society was estimated to 
be about 728 Euro per patient in the case of DPP4i while it was on average 770 Euro 
when considering SU because DPP4i induced lower direct non-health costs related 
to stroke and an overall saving of 20.88 Euro per patient/year due to lower costs 
of productivity loss for hypoglicaemic events and stroke. ConClusions: The use 
of DPP4i was cost-saving from the societal perspective and just the high cost for drug 
acquistion made the adoption of DPP4i more costly than SU for the Italian NHS. This 
result outlined that DPP4i represents a valuable alternative for the management of 
diabetes both from a clinical and economic perspective and costs will be lowered 
overall just intervening on cost for drug acquisition.
PDB98
Cost-MiniMisAtion AnAlysis of sAxAgliPtin CoMPArED to sitAgliPtin 
AnD linAgliPtin As triPlE thErAPy in CoMBinAtion With MEtforMin 
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objeCtives: To evaluate the cost of using the dipeptidyl peptidase-4 inhibitor 
(DPP4i), saxagliptin, compared to sitagliptin and linagliptin, when used as triple 
therapy in combination with metformin and sulphonylurea (met+SU) for the 
treatment of patients with type 2 diabetes mellitus (T2DM) who are inadequately 
controlled on met+SU alone. Methods: Bucher adjusted indirect treatment com-
parisons (ITCs) were performed with regards to the key T2DM outcomes of HbA1c, 
weight and hypoglycaemia compared to sitagliptin and linagliptin. The ITCs found 
no statistically significant differences between saxagliptin compared to either sit-
agliptin or linagliptin in terms of effectiveness (as measured by Hb1Ac change from 
baseline), and saxagliptin was found to be at least as safe as the other therapies. 
Therefore, a cost-minimisation analysis over a 1-year time horizon was developed 
from a UK health care perspective. Drug costs were considered in the model, sourced 
from the British National Formulary (BNF; September 2013). The application of an 
annual discount rate of 3.5% and use of a longer time horizon (up to 5 years) were 
explored in a scenario analysis. Results: Saxagliptin was associated with a yearly 
cost of £410.80 per patient. The yearly cost per patient for sitagliptin was £432.38, 
and the yearly cost per patient for linagliptin was also £432.38, based on drug costs. 
Therefore, saxagliptin has similar costs compared to the other DPP4i’s. Applying the 
annual discount rate and using a longer time horizon, saxagliptin was associated 
with cost-savings of £97.43 per patient over 5 years compared to both sitagliptin 
and linagliptin. ConClusions: Saxagliptin as triple therapy in combination with 
met+SU was shown to be a cost-saving treatment option from a UK health care 
perspective for patients with T2DM who are inadequately controlled on met+SU 
alone. The cost-saving per patient over 5 years was modest, although this may be 
important in a large patient population.
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Cost-EffECtivEnEss of sitAgliPtin vErsus sulfonylurEA As An ADD-on 
thErAPy to MEtforMin in PAtiEnts With tyPE 2 DiABEtEs in A BElgiuM 
sEtting
Chen J.1, Radican L.2, Shankar R.2, Hiver M.3, Qiu Y.2
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objeCtives: Assess the cost-effectiveness of sitagliptin versus sulfonylurea as 
an add-on therapy to metformin among type 2 diabetes patients currently on 
metformin but not achieving HbA1c goal in Belgium. Methods: We employed 
a previously published individual-level simulation model that incorporated risk 
